Mandate

Vinge has advised Titania Holding AB (publ) in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Titania Holding AB (publ) (“Titania”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 November 2021 and the first day of trading was 10 December 2021.

The price in the offering was SEK 20 per class B share, corresponding to a market capitalization of all of Titania’s shares upon completion of the offering of approximately SEK 1.4 billion.

Titania is a fast-growing real estate company focusing on the Stockholm region. Its operations consist of project development, production and management. Titania participates throughout the entire value chain, from early stages of city and project development to land acquisitions, production and rental and eventually also long-term property management. Titania possesses expertise throughout all steps of the value chain and has capacity to carry out large projects within urban development, adding value in terms of increased social and financial sustainability.

Vinge’s team primarily consisted of David Andersson, Amanda Knutsson, Anna Grigorian and Anna Svensson (Capital Markets and Public M&A), Frida Ställborn (Real Estate), Kamyar Najmi and Benjamin Vafaeian (Banking and Finance).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025